Emerging strategies in the diagnosis, prevention and treatment of Chlamydophila pneumoniae infections

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 10, 2008, Pages 1175-1189

  Villegas, Enrique ^a   Camacho, Ana ^b   Carrillo, Jose Antonio ^b   Sorlózano, Antonio ^a   Rojas, José ^b   Gutiérrez, José ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b VIRCELL S L   (Spain)

Author keywords

Chlamydophila pneumoniae; Diagnosis; Prevention; Treatment

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL ANTIGEN; BACTERIAL DNA; CLARITHROMYCIN; DNA VACCINE; ENVELOPE PROTEIN; EPITOPE; FREUND ADJUVANT; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MAJOR OUTER MEMBRANE PROTEIN; OUTER MEMBRANE COMPLEX B PROTEIN; OUTER MEMBRANE PROTEIN; PLACEBO; POLYMORPHIC OUTER MEMBRANE PROTEIN; RNA 16S; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ACUTE CORONARY SYNDROME; ANTIBIOTIC THERAPY; ANTIBODY DETECTION; ANTIGEN DETECTION; ATHEROSCLEROSIS; BACTERIAL CELL; BACTERIAL INFECTION; BACTERIUM CULTURE; CELL CULTURE; CELL CYCLE; CELLULAR IMMUNITY; CHLAMYDOPHILA PNEUMONIAE; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL TRIAL; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE EXPRESSION; HUMAN; IMMUNOFLUORESCENCE TEST; MICROIMMUNOFLUORESCENCE TEST; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PATENT; POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SECONDARY PREVENTION; SERODIAGNOSIS; TISSUE CULTURE; TYPE III SECRETION SYSTEM; VACCINATION;

EID: 56349131776     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.10.1175     Document Type: Review

References (131)

1. Grayston JT, Kuo CC, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995; 92: 3397-400
2. Kuo CC, Shot A, Campbell LA, et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167: 841-9
3. Saikku E Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-6
4. Kuo CC, Chen HH, Wang SP, et al. Identification of a new group of Chlamydia psittaci strains called TWAR. J Clin Microbiol 1986; 24: 1034-7
5. Villegas E, Sorlozano A, Camacho A, Gutiérrez J. Chlamydophila pneumoniae: desde su proteómica hasta la arteriosclerosis. Enferm. Infecc Microbiol Clin 2008; In press
6. Hogan RJ, Mathews SA, Mukhopadhyay S, et al. Chlamydial persistente: beyond the biphasic paradigm. Infect Immun 2004; 72(4): 1843-55
7. Beatty WL, Belanger TA, Desai AA, et al. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun 1994; 62: 3705-11
8. Geisler WM, Suchland RJ, Rockey DD, Stamm WE. Epidemiology and clinical manifestations of unique Chlamydia trachomatis isolates that occupy nonfusogenic inclusions. J Infect Dis 2001; 184: 879-84
9. Peterson EM, de la Maza LM, Brade L, Brade H. Characterization of a neutralizing monoclonal antibody directed at the lipopolysaccharide of Chlamydia pneumoniae. Infect Immun 1998; 66(8): 3848-55
10. Montigiani S, Falugi F, Scarselli M, et al. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun 2002; 70: 368-79
11. Vandahl BB, Birkelund S, Dernol H, et al. Proteome analysis of the Chlamydia pneumoniae elementary body. Electrophoresis 2001; 22: 1204-23
12. Perez Melgosa M, Kuo CC, Campbell LA. Isolation and characterization of a gene encoding a Chlamydia pneumoniae 76-kilodalton protein containing a species-specific epitope. Infect Immun 1994; 62(3): 880-6
13. Bannantine JP, Griffiths RS, Viratyosin W, et al. A secondary structure motif predictive of protein localization to the chlamydial inclusion membrane. Cell Microbiol 2000; 2(1): 35-47
14. Thorpe C, Edwards L, Snelgrove R, et al. Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection. Vaccine 2007; 25(12): 2252-60
15. Molestina RE, Mein JB, Millar RD, et al. Proteornic analysis of differentially expressed Chlamydia pneumoniae genes during persistent infection of HEp-2 cells. Infect Immun 2002; 7(6): 2976-81
16. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992; 82: 158-61
17. Thomas M, Wong Y, Thomas D, et al. Relation between direct detection of Chlamydia pneumoniac DNA in human coronary arteries at postmortem examination and histological severity stary trading of associated atherosclerotic plaque. Circulation 1999; 99(21): 2733-6
18. Bloemenkamp DG, Mali W, Visseren FL, van der Graaf Y. Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design influence results? Am Heart J 2003; 145 (3): 409-17
19. Puolakkainen M, Kuo CC, Shor A, et al. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol 1993; 31: 2212-4
20. Bartels C, Maass M, Bein G, et al. Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. Circulation 1999; 99: 879-82
21. Choussat R, Montalescot G, Collet J, et al. Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and oneyear prognosis of patients with unstable angina pectoris or non-q-wave acute myocardial infarction. Am J Cardiol 2000; 86: 379-84
22. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection? Stroke 2000; 31: 2127-33
23. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb 1993; 13: 1501-4
24. Fong IW. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ 2000; 163(1):49-56
25. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/ Atherosclerosis Study Group. Ann Intern Med 1996; 125(12): 979-82
26. Jackson LA. Campbell LA, Kuo CC, et al. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997; 176: 292-5
27. Maass M, Bartels C, Engel PM, et al. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 31: 827-32
28. Paldanius M, Juvonen R, Leinonen M, et al. Asthmatic persons are prone to the persistence of Chlamydia pneumoniae antibodies. Diagn Microbiol Infect Dis 2007; 59: 117-22
29. Black PN, Scicchitano R, Jenkins CR, et al. Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. Eur Respir J 2000; 15: 254-9
30. Miyashita N, Niki Y, Nakajima M, et al. Chlamydia pneumoniae infection in patients with diffuse panbronchiolitis and COPD. Chest 1998; 114: 969-71
31. Droemarm D, Rupp J, Goldmarm T, et al. Disparate innate immune responses to persistent and acute Chlamydia pneumoniae infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(8): 791-7
32. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the centers for disease control and prevention (USA) and the laboratory centre for disease control (Canada). Clin Infect Dis 200 1; 33: 492-503
33. Boman J, Hammerschag MR. Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin Microbiol Rev 2002; 15: 1-20
34. Boman J, Gaydos CA, Quinn TC. Molecular diagnosis of Chlamydia pneumoniae infection. J Clin Microbiol 1999; 37: 3791-9
35. Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current Status of diagnostic methods. Clin Infect Dis 2007; 44(4): 568-76
36. Apfalter P, Blasi F, Boman J, et al. Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens. J Clin Microbiol 2001; 39: 519-24
37. Kuo CC, Coulson AS, Campbell LA, et al. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg 1997; 26: 29-31
38. Weiss SM, Roblin PM, Gaydos CA, et al. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 1996; 173: 957-62
39. Maass M, Harig U. Evaluation of culture conditions used for isolation of Chlamydia pneumoniae. Am J Clin Pathol 1995; 103: 141-8
40. Madico G, Quinn TC, Boman J, Gaydos CA. Touchdown enzyme time release-PCR for detection and identification of Chlamydia trachomatis, C. pneumoniae, and C. psitraci using the 16S and 16S-23S spacer rRNA genes. J Clin Microbiol 2000; 38: 1085-93
41. Carriflo JA, Gutierrez J, Garcia F, et al. Reliability of multiplex test to detect atypical bacterial DNA in community-acquired pneumonia during childhood. Clin Microbiol Infect 2009; In press
42. Morozurni M, Nakayama E, Iwata S, et al. Simultaneous detection of pathogens in clinical samples from patients with community-acquired pneumonia by real-time PCR with pathogen-specific molecular beacon probes. J Clin Microbiol 2006; 44: 1440-6
43. Loens K, Beck T, Goossens H, et al. Development of conventional and real-time nucleic acid sequence-based amplification assays for detection of Chlamydophila pneumoniae in respiratory specimens. J Clin Microbiol 2006; 44: 1241-4
44. Hardick J, Maldeis N, Theodore M, et al. Real-time PCR for Chlamydia pneumoniae utilizing the Roche Lightcycler and a 16S rRNA gene target. J Mol Diagn 2004; 6: 132-6
45. Apfalrer P, Barousch W, Nehr M, et al. Comparison of a new quantitative ompA-based real-time PCR TaqMan assay for detection of Chlamydia pneumoniae DNA in respiratory specimens with four conventional PCR assays. J Clin Microbiol 2003; 41: 592-600
46. Kuoppa Y, Boman J, Scott L, et al. Quantitative detection of respiratory Chlamydia pneumoniae infection by real-time PCR. J Clin Microbiol 2002; 40: 2273-4
47. Chernesky M, Smieja M, Schachter J, et al. Comparison of an industry-derived LCx Chlamydia pneumoniae PCR research kit to in-house assays performed in five laboratorios. J Clin Microbiol 2002; 40: 2357-62
48. Loens K, Beck T, Ursi D, et al. Two quality control exercises involving nucleic acid amplification methods for detection of Mycoplasma pneumoniae and Chlamydophila pneumoniae and carried out 2 years apart (in 2002 and 2004). J Clin Microbiol 2006; 44(3): 899-908
49. Meijer A, van der Vliet JA, Roholl PJM, et al. Chlamydia pneumoniae in abdominal aortic aneurysms-abundance of membrane components in the absence of heat shock protein 60 and DNA. Arterioscler Thromb Vasc Biol 1999; 19: 2680-6
50. leven M, Goossens H. Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory. Clin Microbiol Rev 1997; 10(2): 242-56
51. Persing DH, Smith TF, Tenover FC, White TJ. Diagnostic molecular microbiology: principles and applications. Washington: American Society for Microbiology, 1993
52. leven MM, Hoymans VY. Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence. J Clin Micribiol 2005; 43: 19-24
53. Paldanius M, Bloigu A, Leinonen M, Saikku P. Measurement of Chlamydia pneumoniae-specific immunoglobulin A (IgA) antibodies by the microimmunofluorescence (MIF) method: comparison of seven fluorescein-labeled anti-human IgA conjugates in a in-house MIF test using one commercial MIF and one enzyme immunoassay kit. Clin Diagn Lab Immunot 2003; 10: 8-12
54. Littman AJ, Jackson LA, White E, et al. Interlaboratory reliability of microimmunofluorescence test for measurement of Chlamydia pneumoniae-specific immunoglobulin A and G antibody titers. Clin Diagn Lab Immunol 2004; 11(3): 615-7
55. Peeling RW, Wang SP, Grayston JT, et al. Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. J Infect Dis 2000; 181 (Suppi 3): S426-9
56. Kutlin A, Roblin PM, Hammerschlag MR. Antibody response to Chlamydia pneumoniae infection in children with respiratory illness. J Infect Dis 1998; 177(3): 720-4
57. Hoymans VY, Bosmans JM, Van Renterghem L, et al. Importance of methodology in determination of Chlamydia pneumoniae seropositivity in healthy subjects and in patients with coronary atherosclerosis. J Clin Microbiol 2003; 41(9): 4049-53
58. Kutlin A. Tsumura N, Emre U, et al. Evaluation of Chlamydia inmunoglobulin M (IgM), Ig G, and Ig A ELISAs Medac for diagnosis of Chlamydia pneumoniae infection. Clin Diagn Lab Immunol 1997; 4: 213-6
59. Hermann C, Graf K, Groh A, et al. Comparison of eleven comercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals. J Clin Microbiol 2002; 40: 1603-9
60. Hermann C, Gueinzius K, Oehme A, et al. Comparison of quantitative and semiquantitative enzyme-linked immunosorbent assays for immunoglobulin G against Chlamydophila pneumoniae to a microimmunofluorescence test for use with patients with respiratory tract infections. J Clin Microbiol 2004; 42(6): 2476-9
61. Gutiérrez J, Mendoza J, Fernández F. ELISA test to detect Chlamydophila pneumoniae IgG. J Basic Microbiol 2002; 42: 13-8
62. Gutiérrez J, de Dios Luna J, Linares J, et al. Relationship between peripheral arterial occlusive disease (PAOD) and chronic Chlamydophila (Chlamydia) pneumoniae infection. A meta-analysis. Thromb Haemost 2005; 93(6): 1153-60
63. Sayvon Diagnostics. WO9857981; 1998
64. Sirs Lab GMBH. WO2007085459; 2007
65. Ehjdel IA. Ehjdel MV, Narezkina AD. RU2241042; 2004
66. Meiji Seika Kaisha. JP2005110545; 2005
67. Gen-Probe, Inc. US2007059735; 2007
68. Cantor Colburn Llp. US2006246473; 2006
69. Finco O, Bonci A, Agnusdei M, et al. Identification of new potential vaccine candidates against Chlamydia pneumoniae by multiple screenings. Vaccine 2005; 23(9): 1178-88
70. Penttilä T. Induction of immunity against experimental Chlamydia pneumoniae infection. Helsinki: University of Helsinki; 2004
71. Bandholtz L, Kreuger MR, Svanholm C, et al. Adjuvant modulation of the immune responses and the outcome of infection with Chlamydia pneumoniae. Clin Exp Immunol 2002; 130(3): 393-403
72. Bergmann-Leitner ES, Leitner WW. Danger, death and DNA vaccines. Microbes Infect 2004; 6: 319-27
73. Puolakkainen M, Parker J, Kuo CC, et al. Further characterization of Chlamydia pneumoniae specific monoclonal antibodies. Microbiol Immunol 1995; 39: 551-4
74. Mygind P, Christiansen G, Persson K, Birkelund S. Analysis of the humoral immune response to Chlamydia outer membrane protein 2. Clin Diagn Lab Immunol 1998; 5: 313-8
75. Ferrero RL, Thilberge JM, Kansau I, et al. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci 1995; 92: 6499-503
76. Gomez FJ, Allendoerfer R, Deepe GS Jr. Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis. Infect Immun 1995; 63: 2587-95
77. Silva CL, Lowrie DB. A single mycobacterial protein (hsp65) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis. Immunology 1994; 82: 244-8
78. Zugel U, Kaufmann SH. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev 1999; 12: 19-39
79. Christiansen G, Ostergaard L, Birkelund S. Molecular biology of the Chlamydia pneumoniae surface. Scand J Infect Dis Suppl 1997; 104: 5-10
80. Knudsen K, Madsen AS, Mygind P. et al. Identification of two novel genes encoding 97- to 99-kilodalton outer membrane proteins of Chlamydia pneumoniae. Infect Immun 1999; 67: 375-83
81. Mygind T, Vandahl B, Pedersen AS, et al. Identification of an in vivo CD4+ T cell mediated response to polymorphic membrane proteins of Chlamydia pneumoniae during experimental infection. FEMS Immunol Med Microbiol 2004; 40(2): 129-37
82. Cornelis GR, Van Gijsegem F. Assembly and function of type III secretory systems. Ann Rev Microbiol 2000; 54: 735-74
83. Univ. California. US6822071; 2004
84. Chiron Corp. WO2005084306; 2005
85. Sefono Genetics Inst SA. US2007053927; 2007
86. Roblin PM, Montalban G, Hammerschlag MR. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother 1994; 38(7): 1588-9
87. Roblin PM, Hammerschlag M. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother 1998; 42(l): 194-6
88. Hammerschlag MR, Roblin PM. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents 2000; 15(2): 149-52
89. Hammerschlag MR, Roblin PM. Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother 2000; 44(5): 1409
90. Gieffers J, Solbach W, Maass M. In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries. Antimicrob Agents Chemother 1998; 42: 2762-4
91. Gieffers J, Füllgraf H, Jahn J, et al. Chlamydia pneumoniae infection in circulating human monocytes is reflactory to antibiotic treatment. Circulation 2001; 103: 351-6
92. Burian K, Berencsi K, Endresz V, et al. Chlamydia pneumoniae exacerbates aortic inflammatory foci caused by murine cytomegalovirus infection in normocholesterolemic mice. Clin Diagn Lab Immunol 2001; 8(6): 1263-6
93. Fong IW, Chiu B, Viira E, et al. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997; 35: 48-52
94. Laitinen K, Laurila A, Pyhala L, et al. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997; 65: 4832-5
95. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin preventsit in a rabbit model. Circulation 1998; 97: 633-6
96. Hu H, Pierce GN, Zhang G. Atherogenic effects of Chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103: 747-53
97. Moazed TC, Campbell LA, Rosenfield ME, et al. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in alipoprotein E-deficient mice. J Infect Dis 1999; 180: 238-41
98. Gupta S, Leathan EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7
99. Gurfinkel C, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999; 20: 121-7
100. Anderson JI, Muhlestein JB, Cadquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. Circulation 1999; 99: 1540-7
101. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000; 102: 1755-60
102. Stone AF, Mendall MA, Kaski JC, et al. Efftct of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: south thames trial of antibiotics in myocardial infarction and unstable angina (STAMINA). Circulation 2002; 106: 1219-23
103. Sinisalo J, Mattila K, Valtonen V, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation 2002; 105: 1555-60
104. Zahn R, Schneider S, Frilling B, et al. Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 2003; 107: 1253-9
105. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003; 290: 1459-66
106. Grayston JT, Kronmal RA, Jackson LA, et al. ACES Investigators. Azitromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637-45
107. Cercek B, Shah PK, Noc M, et al. AZACS Investigators. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003; 361: 809-13
108. Cannon CP, Braunwald E, McCabe CH, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352(16): 1646-54
109. Anderson JL, Muhlestein JB. Antibiotic trials for coronary heart disease. Tex Herat Inst J 2004; 31(1): 33-8
110. Pfizer. US6281199; 2001
111. Pfizer, Inc. US2004082614; 2004
112. Zambon Group S.p.A US2003100614; 2003
113. Kaneka Corp. US6566354; 2003
114. Innate Pharmaceuticals Ab. WO2006132583;2006
115. Aventis Pasteur. US2005220805; 2005
116. Aventis Pasteur. US2005202048; 2005
117. Aventis Pasteur. US2005186266; 2005
118. Murdin AD, Oomen RP, Dunn PL. US2004228874; 2004
119. Murdin AD, Oomen RP, Dunn PL. US2004022801; 2004
120. Aventis Pasteur. US2003225017; 2003
121. Mintz Levin Cohen Ferris Glovs. US2003170259; 2003
122. Aventis Pasteur. US2003161833; 2003
123. Aventis Pasteur. US2003147924; 2003
124. Murdin AD, Oomen RP, Dunn PL. US2003095973; 2003
125. Mintz Levin Cohen Ferris Glovs. US2002150591; 2002
126. Murdin AD, Oomen RP, Wang J. US2002094965; 2002
127. Murdin AD, Oomen RP, Dunn PL. US2002091096; 2002
128. Murdin AD, Oomen RP, Wang J. US20020824021; 2002
129. Aventis Pasteur. US2002081682; 2002
130. Birkelund S, Christiansen G, Pedersen AH, et al. US7264941; 2007
131. Neutec Pharma PLC. US2004029806; 2004